EyePoint Pharmaceuticals stock (US30233B1098): Phase 3 trials clear third safety review

EyePoint Pharmaceuticals received a third consecutive positive safety recommendation for its Phase 3 DURAVYU trials in wet AMD, boosting confidence ahead of mid-2026 topline data. Analysts maintain a Buy consensus with $31.80 price target.

EyePoint Pharmaceuticals (Nasdaq: EYPT) announced that an independent Data and Safety Monitoring Committee (DSMC) issued its third consecutive positive recommendation for the ongoing Phase 3 trials of DURAVYU in wet age-related macular degeneration (AMD). The DSMC reviewed unblinded safety data from the first 200 patients and recommended continuing the trials without modification, according to Stock Titan as of May 2026. This milestone supports EyePoint's path toward potential topline data in mid-2026.

The stock closed at $13.43 on May 13, 2026, on Nasdaq, down 1.40% for the day, according to MarketBeat as of 05/13/2026. Year-to-date, shares are down 26.5% from $18.27. Analysts project a consensus price target of $31.80, implying 136.8% upside, based on eight Wall Street firms with a Buy rating.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: EyePoint Pharmaceuticals, Inc.
• Sector/industry: Biopharmaceuticals / Ocular therapies
• Headquarters/country: United States
• Core markets: US, retinal disease treatments
• Key revenue drivers: DURAVYU, YUTIQ
• Home exchange/listing venue: Nasdaq (EYPT)
• Trading currency: USD

EyePoint Pharmaceuticals: core business model

EyePoint Pharmaceuticals develops and commercializes therapeutics for ocular diseases, leveraging its proprietary Durasert E technology for sustained drug delivery. The platform enables bioerodible implants that release medication over months, reducing treatment burden for patients with retinal conditions. YUTIQ, approved for non-infectious uveitis, generated $0.70 million in Q1 2026 revenue, beating estimates of $0.35 million, per MarketBeat as of 05/13/2026.

DURAVYU, the lead candidate, is in Phase 3 for wet AMD and diabetic macular edema (DME), targeting a market where frequent injections create high unmet needs. The company reported a $1.13 billion market cap as of May 2026.

Main revenue and product drivers for EyePoint Pharmaceuticals

Current revenue stems primarily from YUTIQ sales, with Q1 2026 EPS at ($0.99), missing consensus of ($0.79). The negative net margin stood at 3,566.63% for the trailing twelve months ending Q1 2026, reflecting heavy R&D investment in DURAVYU, according to MarketBeat as of 05/13/2026. Pipeline success could drive growth in the $10+ billion US retinal therapeutics market.

Duravyu targets six-month durability, potentially differentiating from competitors like Eylea requiring monthly dosing. Positive DSMC reviews enhance trial prospects.

Industry trends and competitive position

The ocular therapeutics sector sees rising demand for long-acting treatments amid an aging US population, with wet AMD affecting over 1.6 million Americans. EyePoint competes with Regeneron and Roche but focuses on sustained-release innovations. DURAVYU's Phase 3 progress positions it for potential 2027 approval, per company timelines.

Why EyePoint Pharmaceuticals matters for US investors

Listed on Nasdaq, EyePoint offers US investors exposure to ophthalmology biotech, a segment with strong demand driven by Medicare-covered retinal treatments. Positive trial data could catalyze value in a market where durable therapies command premium pricing.

Conclusion

The third positive DSMC review for DURAVYU Phase 3 trials marks a key de-risking event for EyePoint Pharmaceuticals, supporting its focus on sustained-release ocular therapies. With analyst Buy ratings and substantial upside projected, the stock remains tied to clinical milestones amid biotech volatility. Investors track progress toward mid-2026 data releases.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.